Sandoz Enters Into a $265 Million Settlement Agreement in a U.S. Price-Fixing Case

Swiss generic and biosimilar manufacturer Sandoz SDZ.S on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.

The company said its U.S. subsidiaries had agreed to pay $265 million in a lawsuit with a class of direct drug purchasers, an agreement that does not contain any admission of wrongdoing by the Swiss company.

The agreement, which is subject to court approval, would also release Sandoz of all the claims asserted against it by the settlement class members.

Read the source article at Nasdaq